Skip to contentA
Aptevo Therapeutics Inc.
A
APVOAptevo Therapeutics Inc. Q2 2019 · 10-Q
Revenue$7.36M$7.36M+7.8% vs Q2 2018 Net Income-$13.33M-$13.33MN/M vs Q2 2018 EPS Diluted-$4.14-$4.14N/M vs Q2 2018 Operating Income-$12,896,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aptevo Therapeutics Inc. · CIK 1671584 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$15,891,000N/M Margins · derivedOperating margin-175.2%+7.1 pt vs Q2 2018
Net margin-181.1%+11.4 pt vs Q2 2018
ended Jun 30, 2019 · filed Aug 9, 2019 · 40 d after period end